inv1ncible
Posted - 1 week ago
@A_Train1 another one that comes to mind that got acquired and fail recently is $GBT
JCrispy
Posted - 1 month ago
$GBT BLUE Bluebird Bio unusual call options volume.
Bio2015
Posted - 1 month ago
With $GBT BO fiasco (epic SCD drug failure) that cost $PFE $5B, $BLUE has to be on $PFE radar for BO. SCD obviously a priority with $PFE, along with broader hematology/hemophilia space. Current valuation of $BLUE below cash means Lyfgenia and other 2 drugs have negative value?! Lyfgenia will easily generate $100M+ in 2025. $BLUE cash flow positive by end of 2025.
Exelariad
Posted - 1 month ago
$PFE $GBT this is my stocktwit in 2018 about GBT drug. Pfizer proved I am right and the drug is too toxic. https://stocktwits.com/Exelariad/message/141741704.
Exelariad
Posted - 1 month ago
$GBT this is my stocktwit in 2018 about GBT drug. Pfizer proved I am right and the drug is too toxic. https://stocktwits.com/Exelariad/message/141741704.
biotech
Posted - 09/26/24
$PFE Sickle Cell: pulls $GBT #Oxbryta from global markets and to stop ongoing trials $PFE cites risk of #VOCs + #fatalities GBT deal in 22 was for $5.4B $SGMO Phase3 ready with save zinc finger editing VS $VRTX $CRSP crispr also $SGMO owns BCL11A gene editing Patent $PFE + $SGMO
biotech
Posted - 09/26/24
$SGMO so $PFE in partnership about hemophilia with 220M milestones pending $SGMO chose $PFE for their marketing power... guess they would choose $PFE as well for Fabry Partner... and now suddenly $SGMO sickle cell program gets hot again with $PFE dumping the $GBT product(s) well...
frontiere
Posted - 09/25/24
@PFElinepfrenzy1990 cats are on an intermittent fast again 😞 $PFE Pfizer withdraws Oxbryta ( from $GBT acq) .
Still bullish on the Co though. 2023-2024 the kitchen sink (cleanup) years and then off to 🚀.
https://www.businesswire.com/news/home/20240925201472/en/Pfizer-Voluntarily-Withdraws-All-Lots-of-Sickle-Cell-Disease-Treatment-OXBRYTA%C2%AE-voxelotor-From-Worldwide-Markets
D0C_H0LLIDAY
Posted - 2 months ago
@swamystocks $ALBO $GBT Was in both, both were bought out
Check the charts for these pre buyout
NVDAMillionaire
Posted - 3 months ago
$GBT Global Business Travel Group, Inc. (NYSE: GBTG): Navigating the Evolving Business Travel Landscape http://beyondspx.com/2024/08/05/global-business-travel-group-inc-nyse-gbtg-navigating-the-evolving-business-travel-landscape/
AlexLevin
Posted - 3 months ago
$ESPR officially the past opportunity to recover my biotech money, all other venture seedlings are dead. $GTHX scam saga is finally over today with buyout and I sold to de-leverage on Monday after holding for 3 years. Similar case with $GBT 2 years ago. Never again repeating the same mistake!
Unicorn2020
Posted - 5 months ago
$VNDA Bank of America bought nearly 1,2 million shares in the 1st quarter. Right before Global Blood Therapeutics $GBT got bought out, they also increased their shareholding too. I noticed but was waiting for the price to drop lower, then BOOM. It's gone. I missed the gravy train. Hold for dear life this time. LMAO.
Night_Owl_Biotech
Posted - 7 months ago
$BCRX 's enterprise value ("EV") is 17% of total 10-year analyst consensus revenue estimates. This is roughly half the revenue multiples of peers $PRVB, $CCXI, $GBT & $GWPH when they were acquired (EV's at 32 to 38% of their respective total 10-year revenue estimates per management...as filed in the subsequent 14A/14D9 filings). BCRX's gross margins are higher than all 4. Because BCRX is leveraged, BCRX's market cap would be roughly 150% higher if acquired at these peer revenue multiples (BCRX debt data per Seeking Alpha). BCRX's debt obligations may be higher if liquidated. It has been 41 months since Orladeyo was approved. GBT & GWPH were acquired roughly 33 months after FDA approval. These data points are summarized on the attachment. This is not investment advice. We're only pointing out the math associated with this BCRX "what if." As always, it is also possible our math is wrong. We suggest you research for yourself.
SethTheTrader
Posted - 10 months ago
@Loticicio @ada78 he’s the founder and CIO of Cedar Holdings. Long time shareholder in AudioEye. If you pull up Cedar’s website they have been invested in Perceptive Advisors for a while. This will go off on a bit of a tangent but Perceptive has been one of the best performing biotech funds of the last ~20 years. Run by a guy by the name of Joe Edelman. Team includes all-stars like Adam Stone and Ellen Hukkelhoven (was big on $GBT). Have a few funny stories about Perceptive but it’s no place for Stocktwits. Last thing I’ll say is Perceptive missed Immunomedics, but hey, can’t catch them all. Long way of saying Keith has a decent eye for talent and is increasing his stake in $AEYE, big vote of confidence.
290k
Posted - 10 months ago
Gary: opens 1000x long
Posts: ETF approved!
Gary: closes long and opens 1000x short
Posts: oh no we were hacked you guys!...
🤡
$BTC.X $MARA $MSTR $GBT $QQQ
Iwillplay
Posted - 12/23/23
$BTC.X $GBT Exciting times.
https://finbold.com/how-high-will-bitcoin-go-in-2024-experts-btc-price-predictions/
pole0102
Posted - 11 months ago
$BLUE just saying... Pfizer paid $GBT $5.4 billion for SCD 👀 👀
D0C_H0LLIDAY
Posted - 11/30/23
$XFOR I've had positions in $AIMT $GBT $ALBO before buyouts
As @stealin_your_thunder said... This has all the hallmarks of the above companies.
Rare disease, simple therapies/medicines, excellent C-Suite with direct ties to big pharma
Neutropenia is one of the most deadly obstacles chemo patients face while undergoing treatment. This stock could be a pick and shovel cancer/chemo play down the line.
DoctrBenway
Posted - 10/31/23
$CRSP $BLUE $GBT (bought-out) shorts should be made to watch the patient descriptions of their SCD and its effect on their lives on loop for their eternity in hell.
AlexLevin
Posted - 09/25/23
@sogenerous if there are news you will not have time to re-enter (if this is the sort of news we all expect here), you might regret it. Came through that with $ZGNX and $GBT already.
D0C_H0LLIDAY
Posted - 1 year ago
@WizeKing idk but I hit on $GBT and $AIMT in the not so distant past
$BLRX is legit
Night_Owl_Biotech
Posted - 08/28/23
Would investors familiar with $TSVT review our attachment. We're trying to quantify downside risk to TSVT longer-term outside normal market, regulatory & mgmt competence risks. TSVT trades for less than their 6/30/23 cash & only slightly higher than cash minus all liabilities (excl the lease on their plant which is secured by their validated facility...which would certainly be assumed by any buyer in a M&A scenario). Since FDA approved products are worth a multiple of current/future sales then, in theory, TSVT's valuation ascribes no value to its 50% share of Abecma (LOE is not until 2036). Abecma FY22 sales = $300MM Recent peer M&A transactions ($CTIC $PRVB $GBT $CCXI) suggest products w/LOE in 28-31 are worth ~3X FY28 consensus revenue estimates. Using this metric, assuming 0% growth in Abecma sales thru 28, suggests Abecma is worth $450MM to an acquirer (nevermind the pipeline)? What are we missing? Thank you. As always, we could be very wrong.
AlexLevin
Posted - 1 year ago
@NYtrader458 this is not a buyout rumor, this is BS. You can check the price action when a real buyout rumor appears if you look at $GBT that had a credible rumor spreading around 3 weeks before BO was confirmed officially.
NorthWestHawk
Posted - 1 year ago
I like $ALDX and $VRNA and I've been watching them as potential mustang 🐎 stocks for my portfolio. Unfortunately I missed their big moves so far. Perceptive Advisory owns 19% and 6% of them, respectively. Perceptive is a good Healthcare-focused hedge fund that benefited from biotech baggers such as $RXDX (to be acquired by Merk), $ISEE (to be acquired by Japan's Astellas), $GBT (acquired by Pfizer)... My priority (in this market environment) is to hold undervalued stocks that are owned by top biotech-focused hedge funds such as Baker Bros, BVF Partners, Deep Track, EcoR1, Redmile, and The Column Group though, but I've been watching these 2 stocks very closely...
STCKPRO
Posted - 04/28/23
$GBT:CA NEW ARTICLE : BMTC Group GAAP EPS of $1.23, revenue of $717.9M https://www.stck.pro/news/GBT:CA/48763913/
tickeron
Posted - 03/23/23
Which stock is the best to invest? Compare $CCS vs. $DAC vs. $GBT. #CenturyCommunities https://srnk.us/go/4509392
